Sanofi News

6-K: Sarclisa Recommended for EU Approval by the CHMP to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma and Dupixent sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria

Nov 19 01:26

6-K: Dupixent Approved in the EU as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

Nov 8 00:38

6-K: Dupixent Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

Oct 31 19:00

6-K: Sanofi and Orano Join Forces to Develop Next-Generation Radioligand Medicines and Sanofi and CD&R Partner to Fuel Opella's Ambitions in Consumer Healthcare

Oct 21 23:50

6-K: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants and Sanofi in discussions to sell a controlling stake in Opella

Oct 12 03:39

6-K: Dupixent Approved in China as the First-Ever Biologic Medicine for Patients with COPD and Dupixent Approved in the US as the First-Ever Biologic Medicine for Patients with COPD

Oct 2 23:09

6-K: Colletion of Recent Announcements

Sep 25 02:57

6-K: Colletion of Recent Announcements

Sep 14 00:51

6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis

Sep 3 22:51

6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant

Aug 13 18:10

6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A

Jul 23 23:29

6-K: Colletion of Recent Announcements

Jul 3 02:30

6-K: Colletion of Recent Announcements

Jun 12 01:58

6-K: Sanofi Completes Acquisition of Inhibrx, Inc

May 31 04:37

6-K: Colletion of Recent Announcements

May 29 00:06

Sanofi | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Apr 4 20:50

Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis

Mar 21 02:13

Sanofi | S-8 POS: S-8 POS

Mar 15 20:45

Sanofi | 6-K: Colletion of Recent Announcements

Feb 28 00:41

Sanofi | 6-K: Peer Support, Flexible Work Arrangements, Salary for a Year: Sanofi Launches Global Program for Employees Affected by Cancer and Critical Illnesses

Feb 16 01:12